Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma.

Autor:	Virgen CA; Harvard Medical School, Boston, MA, USA.; Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sparks JA; Harvard Medical School, Boston, MA, USA.; Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA., Nohria A; Harvard Medical School, Boston, MA, USA.; Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA., O'Hare MJ; Harvard Medical School, Boston, MA, USA.; Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA., Goyal A; Department of Dermatology, University of Minnesota, Minneapolis, MN, USA., Said JT; Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Tawa M; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., LeBoeuf NR; Harvard Medical School, Boston, MA, USA.; Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kupper TS; Harvard Medical School, Boston, MA, USA.; Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Fisher DC; Harvard Medical School, Boston, MA, USA.; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Larocca C; Harvard Medical School, Boston, MA, USA.; Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jazyk:	angličtina
Zdroj:	The oncologist [Oncologist] 2023 Aug 03; Vol. 28 (8), pp. e694-e698.
DOI:	10.1093/oncolo/oyad155
Abstrakt:	Mogamulizumab is being increasingly prescribed for the treatment of T-cell lymphomas (MF/SS/ATLL). We conducted a retrospective cohort study to identify muscular immune-related adverse events (irAEs) associated with mogamulizumab in patients with T-cell lymphoma followed at Dana-Farber Cancer Institute from January 2015 to June 2022. We identified 5 cases of mogamulizumab-associated myositis and/or myocarditis (MAM/Mc), 2 additionally affected by myasthenia gravis, among 42 patients with T-cell lymphoma. Three cases experienced -mogamulizumab-associated rash (MAR) prior to developing MAM/Mc. The incidence (n = 5/42, 11.9%) of muscular mogamulizumab-associated irAEs may be higher than has been previously reported in clinical trials and may be of late onset (a median of 5 cycles and as late as 100 days from the last infusion). We highlight the utility of IVIG, together with systemic corticosteroids, for the treatment of these potentially fatal side effects associated with mogamulizumab therapy. (© The Author(s) 2023. Published by Oxford University Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu